Meta-analysis of impact of continuous renal replacement therapy dose on outcome of acute renal failure patients
10.3760/cma.j.issn.1001-7097.2010.12.002
- VernacularTitle:连续性肾脏替代治疗剂量对急性肾衰竭患者预后影响的荟萃分析
- Author:
Hualin QI
;
Feng LIU
;
Jun WANG
;
Chen YU
;
Haidong YAN
- Publication Type:Journal Article
- Keywords:
Renal dialysis;
Hemodiafiltratoin;
Meta-analysis;
Continuous renal replacement therapy;
Mortality
- From:
Chinese Journal of Nephrology
2010;26(12):880-886
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the effect of continuous renal-replacement therapy (CRRT) dose on the outcome of acute renal failure (ARF) patients with meta-analysis of randomized controlled trials (RCTs). Methods Studies were identified by systematic search of peer-reviewed publications in Medline, EMBASE and Cochrane library database through June 2010. All the RCTs that compared the incidence of clinical outcome such as mortality, need for chronic dialysis between standard and low dose CRRT were eligible. The pooled relative risk (RR) for clinical outcome was compiled using a random-effects model. Heterogeneity was evaluated by means of subgroup and sensitivity analysis. Results Six eligible studies were identified. By meta-analysis, standard dose CRRT was associated with non-significant 13% mortality risk reduction (RR 0.87, 95%CI 0.70-1.07, P=0.19)and 13% composite outcome risk reduction of chronic dialysis dependence and mortality (RR 0.87, 95%CI 0.69-1.09, P=0.21), but the trend toward increased chronic dialysis dependence risk among survivors (RR 1.43, 95%CI 0.94-2.18, P=0.09). The overall test for heterogeneity among cohort studies was significant (P=0.001, I2=76.2%). The risk of mortality was modality was significantly lower in some studies of which delivered dose was moer than 35 ml·kg-1·min-1,modality was continuous venous-venous hemofiltration (CVVH) and major cause was non-sepsis treated with standard dose CRRT. Conclusions Standard dose CRRT in patients with ARF does not improve survival, renal recovery and composite outcome, but decreases mortality in important subgroups including those with higher delivered dose, CVVH and non-sepsis.
